Tags

Type your tag names separated by a space and hit enter

Seraph-100 Hemoperfusion in SARS-CoV-2-Infected Patients Early in Critical Illness: A Case Series.
Blood Purif. 2021 Jul 14 [Online ahead of print]BP

Abstract

There is an urgent need for therapeutic interventions to alter the course of critically ill coronavirus disease 2019 (CO-VID-19) patients. We report our experience with the Seraph-100 Microbind Affinity Blood Filter (Seraph-100) in 4 patients with COVID-19 early in the course of their critical respiratory illnesses. Patients were diagnosed with COVID-19 and were admitted to intensive care with worsening respiratory failure but did not require dialysis or vasopressors. Patients had to have a PaO2 to FiO2 (P/F ratio) <150 to qualify for hemoperfusion therapy. All patients received standard medical therapy including oral vitamins C and D and zinc in addition to intravenous dexamethasone and remdesivir. Patients received a single 5- to 7-h session with Seraph-100 on a conventional dialysis machine (Fresenius 2008T) via a nontunneled central venous dialysis catheter with a goal of processing at least 100 L of blood. Patients received weight-based subcutaneous enoxaparin anticoagulation, as well as systemic intravenous heparin (70 units/kg), just prior to hemofiltration. Treatment with Seraph-100 hemoperfusion was well tolerated, and all patients were able to finish their prescribed therapy. All patients treated with Seraph-100 survived to be discharged from the hospital. Well-designed clinical trials are needed to determine the overall safety and efficacy of the Seraph-100 Microbind Affinity Blood Filter in COVID-19 patients.

Authors+Show Affiliations

Hattiesburg Clinic Department of Nephrology, Hattiesburg, Mississippi, USA.Department of Medicine, Uniformed Services University, Bethesda, Maryland, USA.

Pub Type(s)

Case Reports

Language

eng

PubMed ID

34261058

Citation

Rifkin, Brian S., and Ian J. Stewart. "Seraph-100 Hemoperfusion in SARS-CoV-2-Infected Patients Early in Critical Illness: a Case Series." Blood Purification, 2021, pp. 1-4.
Rifkin BS, Stewart IJ. Seraph-100 Hemoperfusion in SARS-CoV-2-Infected Patients Early in Critical Illness: A Case Series. Blood Purif. 2021.
Rifkin, B. S., & Stewart, I. J. (2021). Seraph-100 Hemoperfusion in SARS-CoV-2-Infected Patients Early in Critical Illness: A Case Series. Blood Purification, 1-4. https://doi.org/10.1159/000517430
Rifkin BS, Stewart IJ. Seraph-100 Hemoperfusion in SARS-CoV-2-Infected Patients Early in Critical Illness: a Case Series. Blood Purif. 2021 Jul 14;1-4. PubMed PMID: 34261058.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Seraph-100 Hemoperfusion in SARS-CoV-2-Infected Patients Early in Critical Illness: A Case Series. AU - Rifkin,Brian S, AU - Stewart,Ian J, Y1 - 2021/07/14/ PY - 2021/01/30/received PY - 2021/05/12/accepted PY - 2021/7/14/entrez PY - 2021/7/15/pubmed PY - 2021/7/15/medline KW - Case report KW - Coronavirus disease 2019 KW - Critical illness KW - Extracorporeal sorbent hemoperfusion KW - Seraph-100 SP - 1 EP - 4 JF - Blood purification JO - Blood Purif N2 - There is an urgent need for therapeutic interventions to alter the course of critically ill coronavirus disease 2019 (CO-VID-19) patients. We report our experience with the Seraph-100 Microbind Affinity Blood Filter (Seraph-100) in 4 patients with COVID-19 early in the course of their critical respiratory illnesses. Patients were diagnosed with COVID-19 and were admitted to intensive care with worsening respiratory failure but did not require dialysis or vasopressors. Patients had to have a PaO2 to FiO2 (P/F ratio) <150 to qualify for hemoperfusion therapy. All patients received standard medical therapy including oral vitamins C and D and zinc in addition to intravenous dexamethasone and remdesivir. Patients received a single 5- to 7-h session with Seraph-100 on a conventional dialysis machine (Fresenius 2008T) via a nontunneled central venous dialysis catheter with a goal of processing at least 100 L of blood. Patients received weight-based subcutaneous enoxaparin anticoagulation, as well as systemic intravenous heparin (70 units/kg), just prior to hemofiltration. Treatment with Seraph-100 hemoperfusion was well tolerated, and all patients were able to finish their prescribed therapy. All patients treated with Seraph-100 survived to be discharged from the hospital. Well-designed clinical trials are needed to determine the overall safety and efficacy of the Seraph-100 Microbind Affinity Blood Filter in COVID-19 patients. SN - 1421-9735 UR - https://www.unboundmedicine.com/medline/citation/34261058/Seraph-100_Hemoperfusion_in_SARS-CoV-2-Infected_Patients_Early_in_Critical_Illness:_A_Case_Series. L2 - https://www.karger.com?DOI=10.1159/000517430 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.